Verification of the efficacy of Bromhexine-hydrochloride in treatment of patients with COVID19 disease

Tabriz University of Medical Sciences0 个研究点目标入组 1,300 人开始时间: 待定最近更新: 2021年1月5日

试验速览

暂无简介。

•18 years and older, both sexes
•Having home contact, unmasked contact with a patient with Covid-19 confirmed by RT-PCR or clinical evidence or radiography of pneumonia and acute respiratory distress syndrome (ARDS);
•No clinical signs of Covid-19 (fever, cough, dyspnea, shortness of breath, sore throat, extreme tiredness, digestive problems);
•No chronic respiratory problems or other illnesses that are mistaken for symptoms of COVID-19

•Involvement with any other ongoing studies.
•Pregnant or breast feeding woman or with positive pregnancy test result for fetal safety
•Severe liver disease as a strong confounding factor
•Severe renal failure as a strong confounding factor
•Refusal by attending physician for no clinical equipoise
•Advanced active malignancy as a strong confounding factor
•Patient in other clinical trials for COVID-19 within 30 days before/after ICF as a confounding factor/s
•Other patient characteristics (not thought to be related to underlying COVID-19) that portend a very poor prognosis (e.g, severe liver failure, severe renal failure, and etc. May impact primary and other clinical endpoints- Known allergy to study drug or its ingredients related to renin-angiotensin system (RAS), or frequent and/or severe allergic reactions with multiple medications for patient protection purposes
•Other uncontrolled disease, as judged by investigators that may influence study endpoint and other clinical outcome

发起方